Results 111 to 120 of about 17,302 (216)
ABSTRACT In recent years the addition of the oral BCL2 inhibitor venetoclax to hypomethylating agents (HMAs) has emerged as the standard‐of‐care for patients with acute myeloid leukemia (AML) who are not fit for intensive chemotherapy, significantly improving survival and quality‐of‐life.
Mariarita Sciumè +9 more
wiley +1 more source
Efferocytosis is a key process for macrophages to clear apoptotic cells, which undergoes the “ Find Me” chemotaxis signal stage, the “eat me” phagocytosis recognition stage and the “digest me” digestion stage in turn. During the aforementioned three stages, various signaling molecules released by apoptotic cells can promote the phenotypic polarization ...
Qiuping Chen +3 more
wiley +1 more source
International audience5-Azacitidine, a cytidine analogue and a hypomethylating agent, is a staple drug being in the treatment of myelodysplastic syndromes [1].
El-Makhour, Yolla +4 more
core +1 more source
Purpose Azacitidine is standard, first-line therapy in higher-risk myelodysplastic syndromes (MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce superior overall response rates (ORRs) to azacitidine is not known ...
Olatoyosi Odenike +45 more
core +1 more source
Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang +4 more
wiley +1 more source
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley +1 more source
Background We aimed to characterise the molecular effects of treating myelodysplastic syndrome (MDS) cells with the DNA methyltransferase inhibitor azacitidine and an PIM-2 inhibitor, focusing on their potential synergistic effects.
Yixuan Guo +6 more
doaj +1 more source
Response rates in platinum-resistant ovarian cancer remain low (16–30%) and decline with subsequent lines of therapy. Mirvetuximab soravtansine (MIRV), an antibody–drug conjugate targeting folate receptor alpha (FRα), has demonstrated clinically ...
Sophonie Shilonite Njonou Noujiep +7 more
doaj +1 more source
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba +21 more
wiley +1 more source
European Journal of Haematology, Volume 117, Issue 6, Page 1671-1675, December 2026.
Shira N. Dinner +16 more
wiley +1 more source

